JCO oncology practice · 2024
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shore Neal, Nielsen Sarah M, Esplin Edward D, Antonarakis Emmanuel S, Barata Pedro C, Beer Tomasz M, Beltran Himisha, Bryce Alan, Cookson Michael S, Crawford E David, Dorff Tanya B, George Daniel J, Heath Elisabeth I, Helfand Brian T, Hussain Maha, Mckay Rana R, Morgans Alicia K, Morris Michael J, Paller Channing J, Ross Ashley E, Sartor Oliver, Shen John, Sieber Paul, Smith Matthew R, Wise David R, Armstrong Andrew J
Аннотация
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.